Clinical Trial Update: IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update notes that IASO104 is being evaluated in an early-phase 1 study for relapsed/refractory multiple myeloma and plasma cell leukemia, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• IASO104

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING